Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Sexually Transmitted Diseases (STDs)








Legal Status of EPT in the Commonwealth of the Northern Mariana Islands						Print
																Related Pages
										**permissable symbol EPT is permissible.**
This is a table caption for compliance. Ignore it please.
**I. Statutes/regs on health care providers’ authority to prescribe for STDs to a patient’s partner(s) w/out prior evaluation** (Explanation)
plus symbol “Notwithstanding any other provision of law, a health care provider who is licensed to diagnose and prescribe drugs for a sexually transmitted gonorrhea, chlamydia, or trichomoniasis infection, and who diagnoses a sexually transmitted gonorrhea, chlamydia, or trichomoniasis infection in an adult patient, may provide expedited partner therapy to said patient’s sexual partner or partners, and shall not be subject to civil or professional liability, except for in cases of willful or wanton misconduct, provided that said partner(s) have no known antibiotic allergies, and that the medication/prescription includes clear instructions, and appropriate warnings. Health care providers providing expedited partner therapy shall also provide education to the patient on the treatment strategy, and shall still recommend that the patient’s adult partner(s) see a health care provider in person for STD and HIV testing.” 3 N. Mar. I. Code § 21102
minus symbol “’Patient,’ as used in any context in this Chapter, means a person for whom health care professional services are performed or to whom health care products or services are sold or provided at the site of a health care professional’s practice or through referral to another location or business in which the health care professional has a material interest”  NMIAC § 140-50.3-305***II. Specific judicial decisions concerning EPT (or like practices)** (Explanation)**III. Specific administrative opinions by the Attorney General or medical or pharmacy boards concerning EPT (or like practices)** (Explanation)**IV. Laws that incorporate via reference guidelines as acceptable practices (including EPT)** (Explanation)**V. Prescription requirements** (Explanation)
plus symbol “Notwithstanding any other provision of law, a pharmacist may dispense antibiotic medication prescribed as expedited partner therapy treatment for a patient’s adult sexual partner(s), and shall not be subject to civil or professional liability, except for in cases of willful or wanton misconduct, provided that the medication/prescription includes clear instructions, and appropriate warnings.” 3 N. Mar. I. Code § 21102
minus symbol “The Pharmacist shall not dispense a Prescription Drug if the Pharmacist knows or reasonably should know that the Prescription Drug Order was issued solely on the basis of an Internet-based questionnaire, an Internet-based consultation, or a telephonic consultation, all without a valid Patient-Practitioner relationship”  NMIAC § 140-50.3-3571*minus symbol “’Compounding’ means the preparation of Components into a Drug product (1) as the result of a Practitioner’s Prescription Drug Order or initiative based on the Practitioner/patient/Pharmacist relationship in the course of professional practice, or (2) for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or Dispensing.
Compounding includes the preparation of Drugs or Devices in anticipation of receiving Prescription Drug Orders based on routine, regularly observed prescribing patterns.
[...]
(q) “Dispense” or “Dispensing” means the interpretation, evaluation, and implementation of a Prescription Drug Order, including the preparation and Delivery of a Drug or Device to a patient or patient’s agent in a suitable container appropriately labeled for subsequent Administration to, or use by, a patient.”  NMIAC § 140-50.3-3500*
minus symbol “A Prescription Drug Order shall contain the following information at a minimum: (a) full name, date of birth, and street address or P.O. Box of the patient” NMIAC § 140-50.3-3570***VI. Assessment of EPT’s legal status with brief comments** (Explanation)
**minus symbol EPT is permissible.**Statutory authority expressly authorizes EPT for the treatment of chlamydia, gonorrhea, and trichomoniasis, subject to various conditions as stated in the law*This legal authority predates the effective date of the state’s law that authorizes EPT.
**Status as of October 5, 2018**Legendplus sign supports the use of EPT
minus symbol negatively affects the use of EPT
permissible EPT is permissible
potentially allowable EPT is potentially allowable
prohibited EPT is prohibited
This is a table caption for compliance. Ignore it please.
permissible EPT is permissible in 46 states:
potentially allowable EPT is potentially allowable in 4 states:
prohibited EPT is prohibited in 0 states:AlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOregonPennsylvaniaRhode IslandSouth CarolinaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingEPT is permissible in the District of Columbia.
EPT is permissible in the Commonwealth of the Northern Mariana Islands.
AlabamaKansasOklahomaSouth DakotaEPT is potentially allowable in Puerto Rico and Guam.Show More
****

**Summary Totals**
The information presented here is not legal advice, nor is it a comprehensive analysis of all the legal provisions that could implicate the legality of EPT in a given jurisdiction.  The data and assessment are intended to be used as a tool to assist state and local health departments as they determine locally appropriate ways to control STDs.
For comments, feedback and updates, please contact CDC-INFO: https://www.cdc.gov/cdc-info/.
							
					
							Last Reviewed:  November 3, 2023						Source: 	Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeSexually Transmitted Diseases (STDs)
Diseases & Related Conditionsplus icon
Bacterial Vaginosis (BV)
Chlamydia
Gonorrhea
Hepatitis
Herpes
HIV/AIDS & STDs
Human Papillomavirus (HPV)
*Mycoplasma genitalium (Mgen)*
Pelvic Inflammatory Disease (PID)
STDs & Infertility
STDs during Pregnancyplus icon
Fact Sheet
Detailed Fact Sheet
Statistics
Treatment and Care
Archive
STD Risk and Oral Sex
Syphilis
Trichomoniasis
Other STDsplus icon
Archive
Life Stages and Populationsplus icon
Adolescents and Young Adultsplus icon
Adolescents and Technology
Adolescents and STDs Fact Sheet
Gay, Bisexual and Other MSMplus icon
Gay Men & STDs Fact Sheet
Preventionplus icon
Guidance During Disruption of STD Clinical Services
Just Diagnosed?
Which STD Tests Should I Get?
STD Lowdown Infographic
Program Management & Evaluation Toolsplus icon
Effective Interventions
Gap Assessment Toolkit
Internet Partner Services Toolkit
Outbreak Response Resourcesplus icon
Congenital Syphilis HAN Template
Disseminated Gonococcal Infection HAN Template
Gonorrhea with Reduced Susceptibility HAN Template
LGV HAN Template
Practical Use of Program Evaluation
Program Operations Guidelines
S.P.A.C.E. Monkey
STD Informatics and Surveillance
Projects & Initiativesplus icon
EHE: Scaling Up HIV Prevention Services in STD Specialty Clinics
Gonococcal Isolate Surveillance Project (GISP)
Disease Interventionplus icon
Disease Intervention Training Centers
National Disease Intervention Specialists (DIS) Recognition Day
Resources
National Network of Prevention Training Centers (NNPTC)
STD PCHDplus icon
CDC DIS Workforce Development Funding
Guidance
STD Health Equityplus icon
Community Approaches to Reducing STDs
Sexual Health Cultural Competence Resources
Archive
STD Surveillance Network (SSuN)
Archive
Statisticsplus icon
STI Surveillance 2022
Gonococcal Isolate Surveillance Project Profiles
Syphilis Supplement
STI Prevalence, Incidence, and Cost Estimatesplus icon
At A Glance
Social Media Materials
Indian Health Service Reports
Social Media & Moreplus icon
The State of STIs Infographicplus icon
Customizable
HTML version
SDSB Contacts
Archive
Tools & Materialsplus icon
Brochuresplus icon
The Facts Brochures
Fact Sheets
Infographics
Provider Pocket Guides
Social Media Resources
Videos and Podcastsplus icon
Let’s Talk About Sexual Health
Safe in the City
Webinars
Widgets
Archive
Trainingplus icon
STD Prevention Courses
SASSI – SAS Training
STD Clinical Slidesplus icon
STD Clinical Slides
STD Picture Cardsplus icon
STD Picture Cards
Treatment and Screeningplus icon
Availability of STI Testing & Treatment Products
Duty to Warn
Expedited Partner Therapyplus icon
Gonorrhea Guidance
Legal Status of EPT
Legal/Policy Toolkit
Laboratory Information
Prenatal Syphilis Screening Laws
STD QCSplus icon
STD QCS Webinar Questions
STI Treatment Guidelines, 2021
A Guide to Taking a Sexual History
Additional Resources
Archive
About the Division of STD Preventionplus icon
STI Funding at Workplus icon
STI Prevention Success Stories
Success Bulletins
Strategic Plan 2022-2026
Fundingplus icon
Funding Archive
Archive


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue